EUVIMEDEUVIMED entdecken
Systematische Übersicht

Retrograde cricopharyngeal dysfunction and treatment with botulinum toxin: a systematic review

Clara Helena Jönsson, Christina Caroline Plaschke

European Archives of Oto-Rhino-Laryngology · 2024

DOI: 10.1007/s00405-024-08619-8 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Clara Helena Jönsson und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. vsd141@alumni.ku.dk. Hauptthemen laut MEDLINE: Botulinum Toxins, Deglutition Disorders, Esophageal Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Retrograde cricopharyngeal dysfunction (RCPD) is a disease first described systematically in 2019. The main symptom is inability to belch due to cricopharyngeal muscle dysfunction. Other symptoms include gurgling noises, chest pain, bloating, and excessive flatulence. This paper aims to describe RCPD, the aetiology and diagnosis, treatment options, follow-up, and treatment with botulinum toxin (BT). METHODS: A systematic review was done according to the PRISMA guidelines, using the databases PubMed, Embase, and Cochrane at 8/3/2024. The search combined BT with different descriptions of RCPD. All papers were screened by two authors. RESULTS: 120 papers were identified in the search. After screening 13 papers describing 472 patients in total were included. Mean age was 29.3 years with 51.1% men. Diagnosis was established in 82.4% of the cases by symptomatology, 2.1% by high-resolution manometry, and 15.3% by oesophagoscopy. The mean amount of BT was 66 units (U). Mean follow-up time was 13 months. After 1-4 weeks 93.7% had an effect post-treatment and 81.0% after 6 months. Common symptoms were inability to belch (99.8%), chest pain and/or bloating (95.4%), gurgling noises (84.9%), and excessive flatulence (75.9%). Common complications were mild and transient dysphagia (59.4%) and reflux (35.4%). CONCLUSION: The accumulated numbers of patients with RCPD indicates a growing attention to the plausible condition. Injection with BT is a good and safe treatment of RCPD. Most patients only experience mild and transient complications to the treatment. Much is still unknown about RCPD and conditions for setting the diagnosis needs to be evaluated and established internationally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum ToxinsDeglutition DisordersEsophageal DiseasesHumansNeuromuscular AgentsEsophageal Sphincter, Upper

Stichwörter der Autor:innen

AbelchiaBotulinum toxinCricopharyngeal dysfunctionInability to belchUpper oesophageal sphincter dysfunction

Substanzen

Botulinum ToxinsNeuromuscular Agents

Autor:innen und Institutionen

  • University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. vsd141@alumni.ku.dk.
  • Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Institute for Clinical Medicine, Copenhagen University Hospital Rigshospitalet, 9 Blegdamsvej 2100, Copenhagen, Denmark.

Zitieren

APA

Jönsson, C. H., & Plaschke, C. C. (2024). Retrograde cricopharyngeal dysfunction and treatment with botulinum toxin: a systematic review. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08619-8

Vancouver

Jönsson CH, Plaschke CC. Retrograde cricopharyngeal dysfunction and treatment with botulinum toxin: a systematic review. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08619-8

BibTeX
@article{Jnsson2024,
  author = {Jönsson, Clara Helena and Plaschke, Christina Caroline},
  title = {Retrograde cricopharyngeal dysfunction and treatment with botulinum toxin: a systematic review},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2024},
  doi = {10.1007/s00405-024-08619-8}
}
Kostenlos starten →